SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

Escalating US-Israeli strikes on Iran are fueling intense community discussion around USO, with many anticipating significant oil price spikes and a global supply shock as shipping through the vital Strait of Hormuz faces increasing disruptions.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Escalating Middle East tensions, including strikes on Iran and concerns over disruptions in the vital Strait of Hormuz, are driving a surge in crude oil prices and fueling community discussion around Indonesia Energy Corp Ltd's potential for a significant short squeeze given its low float.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is surging as escalating Middle East tensions, particularly involving Iran and threats to the Strait of Hormuz, are driving strong community conversation around a significant potential for global oil supply disruption. Traders are widely discussing a rotation into energy, anticipating XLE will benefit from a material rise in crude prices.

Codatta

Codatta (XNY) is trending as the crypto community highlights its impressive price resilience and ability to show strength even during broader market pullbacks, leading to active discussions around its consistent breaking of resistance and establishing new support levels for potential further upside.

CECO Environmental Corp. engages in the provision of engineering technology and solutions. It offers services in the field of environment, energy, fluid handling, and filtration. The firm operates through the following segments: Energy Solutions, Industrial Solutions and Fluid Handling Solutions. The Energy Solutions segment improves air quality and solves fluid handling needs with market engineered, and customized solutions for the power generation, oil and gas, and petrochemical industries. The Industrial Solutions segment serves the industrial pollution control market. The Fluid Handling Solutions segment provides pump and filtration solutions that maintain safe and clean operations in some of the most harsh and toxic environments. The company was founded by Phillip DeZwirek in 1966 and is headquartered in Austin, TX.

Ceco Environmental Corp.

CECO Environmental is trending due to its recent $2.2 billion Thermon acquisition, aimed at creating a global leader in environmental and thermal solutions, though the news prompted a surprising sell-off despite raised 2026 guidance. The community is actively debating whether the dip is an unjustified reaction and a buying opportunity, contrasting it with the company's strong backlog and optimistic analyst ratings.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE is trending as a community-driven memecoin, hailed as the "third frog" and the official representation of Pepe's post-4chan experience, leveraging a diehard community that champions its unique narrative. The community is actively discussing its impressive resilience and immense upside potential as a micro-cap project within the prominent frog-themed crypto meta.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid escalating Middle East conflict following US/Israeli strikes and Iranian retaliation, leading to intense market debate over a potential downturn driven by rising oil prices or a quick rebound on hopes for a swift resolution.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as escalating U.S.-Iran tensions and military posturing drive concerns over potential oil supply disruptions, particularly in the critical Strait of Hormuz, leading the community to anticipate substantial gains for the energy giant.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as escalating Middle East tensions fuel speculation of oil price spikes, with the community actively debating if these geopolitical risks and the company's strategic positioning in Venezuela are fully priced into the broadly outperforming energy sector.

Confluent, Inc. engages in creating a data infrastructure platform focused on data in motion. The firm provides application architecture engagement, multi data center, security and upgrade engagement, and Amazon web services cloud deployment services. Its products include Confluent Cloud, Confluent Platform, WarpStream BYOC, Connectors, Flink, Stream Governance, and Confluent Hub. The company was founded by Edward Jay Kreps, Neha Narkhede, and Jun Rao on September 1, 2014, and is headquartered in Mountain View, CA.

Confluent Inc - Ordinary Shares Class A

Confluent Inc

Confluent is actively trending following the confirmed $11 billion all-cash acquisition by IBM for $31 per share, sparking community discussion around why the stock isn't precisely at the buyout price and how Confluent's real-time data streaming platform strengthens IBM's AI and hybrid cloud ambitions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Upgraded by Zacks Research

Zacks Research upgraded shares of MoonLake Immunotherapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Earnings Results

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.97) earnings per share (EPS) for the quarter, meeting the...

Lifesci Capital Has Optimistic Outlook of MLTX Q4 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Stock analysts at Lifesci Capital raised their Q4 2025 EPS estimates for shares of MoonLake Immunotherapeutics in a report released on...

Needham & Company LLC Issues Positive Forecast for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price

Needham & Company LLC increased their price objective on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $30.00

BTIG Research increased their price objective on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the stock a "buy" rating in a report on Monday...

MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins

MoonLake Immunotherapeutics (NASDAQ:MLTX) used its Investor Day presentation to outline updates across its clinical portfolio for sonelokimab (SLK), a tri-specific nanobody designed to inhibit IL-17A...

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets Stock futures slumped after Trump's weekend tariff tantrum added uncertainty to American trade policy and was another blow to bullish...

<ul class="summary-bullets"><li>President Donald Trump announced over the weekend that global tariffs would rise from 10% to 15%.&nbsp;</li><li>Traders are also watching last-ditch nuclear negotiations with Iran scheduled in Geneva later this week.&nbsp;</li><li>Nvidia earnings later this week could define the next leg of the market.</li></ul>U.S. stock futures were sharply lower early Monday as investors grappled with a renewed tariff uncertainty, rising geopolitical tensions with Iran, and awaited Nvidia's big earnings report later this week. Last week’s momentum is being tested by President Donald Trump’s announcement over the weekend of a hike in global tariffs from 10% to 15%, which came a day after the Supreme Court struck it down as ‘anti-American.’The markets are also watching last-ditch nuclear talk attempts with Iran in Geneva this Thursday, amidst reports that the U.S. is considering significant military action if diplomacy fails.&nbsp;As of 3:00 a.m. ET on Monday, Nasdaq futures fell 0.6%, the S&amp;P 500 and Dow futures declined 0.5%, while Russell 2000 futures were down nearly 1%.Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has moved to ‘bearish’ from ‘neutral’ last week, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bearish’ amid high message volumes.&nbsp;On the other hand, precious metals have seen a breakout, with gold rising above $5,100 and silver nearing $88/oz.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;The chip giant reports earnings on Feb 25. Beyond its guidance, all eyes will be on its commentary on AI hype, investments, and sustainability.Netflix (NFLX):&nbsp;The stock is facing potential downward pressure after President Trump threatened consequences if board member Susan Rice is not removed. This adds another layer of uncertainty as it pursues its bid for Paramount Skydance (PSKY).&nbsp;Honeywell (HON):&nbsp;It has entered into an amended deal to acquire Johnson Matthey’s Catalyst Technologies business for $1.8 billion.Vanda Pharmaceuticals (VNDA):&nbsp;The US FDA has approved Bysanti for bipolar I disorder and schizophrenia.Moonlake Immunotherapeutics (MLTX):&nbsp;Positive Phase 2 data for its spinal disease drug have led to strong after-hours gains. Traders will be watching this stock closely as we head into a new week.&nbsp;Immunity Bio (IBRX):&nbsp;This biotech stock continues to garner retail attention. Executive chairman Patrick Soon-Shiong&nbsp;<a href="http://stocktwits.com/news-articles/markets/equity/ibrx-stock-open-week-on-high-chairman-teases-anktiva-3-year-expansion-plans-cancer-breakthrough/cZRtSeQR4Us">teased</a> a detailed three-year expansion roadmap, with a detailed press release expected on Monday.&nbsp;Deere &amp; Co (DE):&nbsp;One of the most actively traded stocks last week saw a downgrade to ‘Underperform’ from Jefferies, with a target price of $550. The analyst believes it is already ‘discounted a full recovery’ and trades at steep valuations.&nbsp;Rolls-Royce (RYCEY): The company is reportedly preparing a buyback program of up to €1.5 billion.Other tickers trending on Stocktwits at the time of writing included Capricor Therapeutics (CAPR), Kraft Heinz Co (KHC), Oklo Inc (OKLO), and Ardelyx (ARDX), among others.&nbsp;Other Catalysts To WatchOn the economic front, investors will be monitoring the release of factory orders at 10:00 am ET. They will also be watching for commentary from Fed Governor Christopher Wallace before the bell today.&nbsp;On the earnings radar, investors will be watching for the quarterly reports from Domino’s Pizza (DPZ), GeneDX (WGS), Freshpet (FRPT), and Dominion Energy (D), among others, before the bell&nbsp;today. Also watch out for Hims &amp; Hers (HIMS), Keysite Technologies (KEYS), and Diamonback Energy (FANG) that report after market close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 

Equity

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 


<ul class="summary-bullets"><li>Phase 2 S-OLARIS trial data showed 81% of patients improved within 12 weeks, meeting the primary endpoint.</li><li>Imaging and biomarker results confirming reduced spine inflammation, while no new safety issues were identified.</li><li>MoonLake enters Investor Day with funding in place into the second half of 2027, supported by $394 million in cash.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. (MLTX) surged over 10% in overnight trading on Sunday ahead of Monday’s Investor Day, as newly released clinical data for its experimental spine disease drug reignited investor interest after a volatile year marked by a major setback.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> jumped over 3% on Friday to hit $18.77, but ended 0.3% lower in after-hours trading.&nbsp;<h2 class="st-heading-2">Phase 2 Trial In Spine Disease Meets Primary Endpoint&nbsp;</h2>On Sunday, the company reported positive topline results from a Phase 2 clinical trial of Sonelokimab (SLK) in patients with axial spondyloarthritis, a chronic inflammatory disease that causes severe back pain, stiffness, and progressive loss of mobility.&nbsp;MoonLake said its Phase 2 S-OLARIS trial showed that 81% of patients treated with SLK saw clear improvement in their condition within 12 weeks. The trial met its primary endpoint, using the same standard doctors and regulators rely on to judge whether new treatments for this disease reduce pain, inflammation, and limits on daily movement.MoonLake reported that more than 80% of patients also showed clinically important improvement on additional disease activity measures by Week 12. These clinical gains were supported by imaging results, with MRI scans showing reductions in inflammation inside affected joints.PET imaging further showed a reduction in both inflammation and osteoblast activity within the sacroiliac joints by Week 12. Osteoblast activity is a key driver of irreversible bone formation and progressive loss of mobility in axial spondyloarthritis. Tests on patients’ blood and tissue showed that the drug quickly and consistently reduced the inflammation signals that drive the disease to worsen over time.The company said the safety profile of SLK in the S-OLARIS trial was consistent with previous studies and that no new safety signals were identified.&nbsp;<h2 class="st-heading-2">Cash Position Extends Runway Into 2027</h2>MoonLake reported that it ended 2025 with $394 million in cash, cash equivalents, and short-term marketable securities. The company said this, combined with proceeds from a recent $75 million equity raise, is expected to fund operations into the second half of 2027.The company also announced an amended debt facility with Hercules Capital, including a $25 million drawdown and up to $400 million in additional non-dilutive funding available to support future needs.<h2 class="st-heading-2">Why The Data Matters&nbsp;</h2>The Phase 2 readout marks a positive development for MoonLake following a sharp selloff in September 2025, when one of its Phase 3 trials in a separate skin disease indication failed to meet its primary endpoint. That result triggered a roughly 90% collapse in the stock price over two sessions and sparked a securities class-action lawsuit filed in December.MoonLake will host its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-heads-into-investor-day-with-fda-momentum/cZRjp7xR4wl">Investor Day</a> on Feb. 23, with presentations from its CEO, chief scientific officer, and CFO, followed by an open Q&amp;A session. The company will also discuss the outcomes of its recent Type B meeting with the U.S. Food and Drug Administration (FDA) regarding hidradenitis suppurativa, including next steps related to label strategy and the planned biologics license application submission.&nbsp;Additionally, the company plans to share an interim analysis of the continued response to SLK beyond Week 16 from the Phase 3 Vela trials in adult patients with hidradenitis suppurativa, as well as interim data from the Vela-Teen Phase 3 trial in adolescent patients.MoonLake said the Investor Day will also include an update on its financial position and a review of key 2026 catalysts. These include upcoming data releases from the Phase 3 Izar trials in psoriatic arthritis, as well as the planned Phase 3 development program in palmoplantar pustulosis.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for MLTX was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_34534e245f.webp" alt="mltx ss.png" width="961" height="144"><figcaption>MLTX sentiment and message volume as of February 22 | Source: Stocktwits</figcaption></figure>One user said, “I didn't think were were getting the financials until Wednesday. &nbsp; Looks very positive to me.&nbsp; Tomorrow should be epic, shorts might wanna cover ASAP.”<stembedurl>https://stocktwits.com/DerekVtx/message/645569026</stembedurl>Another user said, “Today had amazing news, tomorrow morning will have many announcements but there are many more to follow. This is like top 10 roadmaps for any drug company right now”&nbsp;<stembedurl>https://stocktwits.com/LouKojak/message/645565865</stembedurl>MLTX stock has risen 42% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown

 Investors are now turning to Monday’s Investor Day for regulatory clarity, pipeline updates, and key 2026 catalysts.

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given New $12.00 Price Target at Royal Bank Of Canada

Royal Bank Of Canada boosted their price target on shares of MoonLake Immunotherapeutics from $10.00 to $12.00 and gave the stock a "sector perform" rating in a research note on Friday...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

MLTX
MoonLake Immunotherapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MLTX News

MLTXMoonLake Immunotherapeutics